BACKGROUND: Only one study reports prednisone to prolong survival in dogs with chronic hepatitis irrespective of the causative agent. The aim of this retrospective study was to investigate the effects of prednisolone treatment on survival, clinicopathological variables, and histological grade and stage of idiopathic chronic hepatitis in 36 dogs. ANIMALS AND METHODS: Medical records were reviewed of 36 prednisolone-treated dogs (median age: 8.6 years; range: 2.0-14.6 years) with chronic hepatitis not associated with primary copper accumulation. Clinicopathological results were analyzed pair-wise for 20 dogs, before and after oral prednisolone administration (1 mg/kg BW/day). Dogs were treated for at least 6 weeks, and for an additional 6 weeks if hepatitis was still present at rebiopsy. Follow-up data pertaining to clinical outcome and survival time (Kaplan-Meier estimate procedure) were analyzed. RESULTS: At the follow-up, 11 dogs were in complete remission, 8 dogs had recurrent clinical signs, and 17 dogs had residual disease. Despite treatment, 20 dogs died of hepatitis-related causes. Dogs without cirrhosis survived significantly longer than dogs with cirrhosis. Prednisolone treatment normalized coagulopathies associated with chronic idiopathic hepatitis within one week in all 10 dogs that had coagulopathies at initial diagnosis. CONCLUSIONS: Our findings suggest that prednisolone has, in part, beneficial effects on hepatic inflammation and that it may, at least in some cases, limit the progression of fibrosis, which emphasizes the importance of early diagnosis and treatment. We did not see any benefit of prednisolone treatment for dogs with cirrhosis. We could document a highly favorable effect of prednisolone treatment on the coagulopathy associated with canine chronic idiopathic hepatitis.
BACKGROUND: Only one study reports prednisone to prolong survival in dogs with chronic hepatitis irrespective of the causative agent. The aim of this retrospective study was to investigate the effects of prednisolone treatment on survival, clinicopathological variables, and histological grade and stage of idiopathic chronic hepatitis in 36 dogs. ANIMALS AND METHODS: Medical records were reviewed of 36 prednisolone-treated dogs (median age: 8.6 years; range: 2.0-14.6 years) with chronic hepatitis not associated with primary copper accumulation. Clinicopathological results were analyzed pair-wise for 20 dogs, before and after oral prednisolone administration (1 mg/kg BW/day). Dogs were treated for at least 6 weeks, and for an additional 6 weeks if hepatitis was still present at rebiopsy. Follow-up data pertaining to clinical outcome and survival time (Kaplan-Meier estimate procedure) were analyzed. RESULTS: At the follow-up, 11 dogs were in complete remission, 8 dogs had recurrent clinical signs, and 17 dogs had residual disease. Despite treatment, 20 dogs died of hepatitis-related causes. Dogs without cirrhosis survived significantly longer than dogs with cirrhosis. Prednisolone treatment normalized coagulopathies associated with chronic idiopathic hepatitis within one week in all 10 dogs that had coagulopathies at initial diagnosis. CONCLUSIONS: Our findings suggest that prednisolone has, in part, beneficial effects on hepatic inflammation and that it may, at least in some cases, limit the progression of fibrosis, which emphasizes the importance of early diagnosis and treatment. We did not see any benefit of prednisolone treatment for dogs with cirrhosis. We could document a highly favorable effect of prednisolone treatment on the coagulopathy associated with canine chronic idiopathic hepatitis.
Authors: K Dirksen; I A Burgener; J Rothuizen; T S G A M van den Ingh; L C Penning; B Spee; H Fieten Journal: J Vet Intern Med Date: 2017-05-23 Impact factor: 3.333
Authors: Manabu Sakai; Bart Spee; Guy C M Grinwis; Louis C Penning; Monique E van Wolferen; Luc J W van der Laan; Hille Fieten Journal: J Vet Intern Med Date: 2018-12-11 Impact factor: 3.333
Authors: Cynthia R L Webster; Sharon A Center; John M Cullen; Dominique G Penninck; Keith P Richter; David C Twedt; Penny J Watson Journal: J Vet Intern Med Date: 2019-03-07 Impact factor: 3.333
Authors: Scott Kilpatrick; Margaret Dreistadt; Polly Frowde; Roger Powell; Elspeth Milne; Sionagh Smith; Linda Morrison; Adam G Gow; Ian Handel; Richard J Mellanby Journal: PLoS One Date: 2016-01-25 Impact factor: 3.240